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EPACs – epigenetic regulators that affect cell survival in cancer 
 
Catherine Murari-Kanti, Ph.D.  
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Supervisor: Michael G. Brattain, Ph.D 
Cyclic adenosine monophosphate (cAMP) is a second messenger responsive to 
many external stimuli, playing an important role in cellular gene expression, 
metabolism, migration, differentiation, hypertrophy, apoptosis and secretion. All 
of these cellular functions are important in many diseases including cancer. Most 
of its effects were initially attributed to the classical protein kinase A (PKA) 
protein, but cellular functions such as proliferation and migration were found to 
be PKA independent and dependent on the newly discovered exchange proteins 
directly activated by cAMP (EPACs). EPACs are single polypeptides that 
primarily function as guanine exchange factors (GEFs) for Rap proteins that 
allow the replacement of guanine diphosphate (GDP) with the more abundant 
guanosine triphosphate (GTP), under cAMP stimulation.  
EPAC has been reported to promote cancer cell growth and activate 
phosphhatidylinositol 3-kinase (PI3K) in direct opposition to the effects of PKA. 
This was confirmed in the Brattain Laboratory, treating colorectal cancer (CRC) 
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cell lines with the EPAC specific activator 8CPT (8-pCPT-2-O-Me-cAMP) 
induced AKT expression along with increased expression of inhibitor of 
apoptosis protein  (IAP) survivin and X-linked IAP (XIAP); which are implicated 
with poor prognosis in cancer. However, there are 2 isoforms of EPAC – EPAC1 
and 2 and to dissect which EPAC is pro-tumorigenic we used EPAC specific 
inhibitors (ESI) – ESI09 (inhibits EPAC1 and 2), ESI05 (inhibits EPAC2) and 
CE3F4 (inhibits EPAC1) and confirmed that EPAC1 is associated with cell 
survival in CRC cell line as well as in pancreatic cancer (PaCa) cell lines.  
Inhibition of EPACs decreased histone deacetylase (HDAC) 4 and 5 that are 
overexpressed in many cancers. Inhibition of HDAC4 and 5 with LMK235 
decreased survivin and XIAP allowing us to hypothesize that the cell survival 
effects observed on EPAC inhibition must be due to the repression of HDACs 4 
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EPACs – epigenetic regulators that affect cell survival 
Catherine Murari-Kanti, Ph.D. 
University of Nebraska Medical Center, 2015 
Introduction: 
3’,5’ -cyclic adenosine mono-phosphate (cAMP) is a second messenger produced 
intracellularly by the action of adenylyl cyclase on adenosine triphosphate (ATP) 
as an output of G-protein coupled receptor signaling. cAMP is involved in 
multiple cell processes such as cell proliferation, metabolism, adhesion, 
apoptosis, gene expression and differentiation, all of which are pivotal in 
numerous diseases, including cancer [1]. 
The cell functions of cAMP were first thought to be solely mediated by Protein 
kinase A (PKA) but it was later discovered that Exchange factor activated by 
cAMP (EPAC) was also involved [2-4]. EPACs are most commonly involved as 
the guanine exchange factor (GEF) for Rap proteins. Upon binding cAMP, EPAC 
undergoes a conformational change that allows Rap to bind to EPAC and replace 
guanosine diphosphate (GDP) with the more abundant guanine triphosphate 
(GTP) [5]. In mammals, Rap guanine nucleotide exchange factors 3 and 4 
(RAPGEF3 and 4) encode for EPAC1 and EPAC2 respectively. EPAC1 is 
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conserved in chimpanzee, Rhesus monkey, dog, cow, rat, chicken and mouse 
while EPAC2 is additionally conserved across zebra fish, fruit fly, C.elegans and 
mosquito.  
RAPGEF3 (EPAC1) is located on chromosome 12 and has 2 isoforms: EPAC1a 
(923 amino acids) and EPAC1b (881 amino acids). For the purpose of this 
document, we will be considering EPAC1a as EPAC1. RAPGEF4 (EPAC2) is 
located on Chromosome 2 and has 3 isoforms – EPAC2a, EPAC2b and EPAC2c 
[6, 7].  
Structure of EPACs: 
The N-terminus of EPAC is the regulatory domain while the C-terminus is the 
catalytic domain. The cyclic nucleotide binding domain(s) (CNB) and the 
disheveled-Egl-10-Pleckstrin (DEP) domain make up the regulatory domain 
while the catalytic domains consist of the Ras-exchange motif (REM), Ras 
association domain (RA) and the CDC25 homology domain (CDC25HD). All 
isoforms of EPAC except EPAC2a possess one CNB domain. The extra CNB 
domain in EPAC2A has no other effect but binds to cAMP with a 20-fold lower 
affinity than the shared CNB. The DEP domains are essential in 
compartmentalization of EPACs within the cell through protein-protein or 
protein-membrane interactions [8, 9]. (Figure 1) 
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 The catalytic domains are highly homologous between EPAC1 and EPAC2. The 
REM domain is essential for stabilizing EPAC while the RA domain in EPAC2 is 
able to bind to activated Ras and allow for the transfer of EPAC2 to Ras 
containing membranes in proximity to Rap [10]. This association is not observed 
in EPAC1. The CDC25HD is responsible for performing the catalytic GEF activity 
for Ras-like GTPases.  
The regulatory region associates with the catalytic region in such fashion to 
confer an auto-inhibitory configuration and thus prevent GEF activation [8]. 
When cAMP binds to the CNB domain of EPACs it causes the EPAC structure to 
open up allowing binding of Rap-GTP. (Figure 2.) 
Although EPAC has been associated with GTPase activity, some activity of this 
cAMP-dependent protein appears to be independent of GTPase activity. These 









Figure 1. The DEP (Dishevelled, Egl-10 and Pleckstrin), CNB (cyclic nucleotide 
binding domain), REM (Ras exchange motif domain), RA (Ras association 
domain) and the CDC25HD (CDC25 homology domain) make up the domain 






Figure 2: Activation of EPACs. Inactive EPAC is folded upon itself and upon 
cAMP binding to the CNB domain, the structure opens up at right angles to 











Location and Functions of EPAC:  
EPAC1 is more ubiquitously distributed in the body than EPAC2. There is higher 
prevalence of EPAC1 in the kidney, ovary, skeletal muscle and thyroid [11].  
EPAC1 levels change during development and are at their peak at about 3 weeks 
after birth [12]. During interphase, EPAC1 is found on the nuclear membrane 
and mitochondria and later is localized to the spindle, centrosome and contractile 
ring during mitosis, in COS7 cells [9]. Varying levels of cAMP in the cell affect 
the localization of EPAC1. High levels of intracellular cAMP allows for EPAC1 to 
bind to phosphatidic acid via the DEP domain and bring it to the plasma 
membrane, while low levels direct EPAC1 to the microtubule cytoskeleton [9, 13, 
14]. 
EPAC2 has specific localization in the human body – in the brain, in endocrine 
glands such as the pituitary and pancreas and the heart [6]. The EPAC2C isoform 
is specifically observed in the liver, where it may control bile acid stimulated 
canalicular formation [7, 15].  
Localization and compartmentalization of EPAC depends on the availability and 
the removal of cAMP. Phosphodiesterases are responsible for the degradation for 
cAMP and cGMP while A-kinase anchoring proteins (AKAPs) are scaffolding 
proteins responsible for retaining EPAC and allowing for downstream signaling 
7 
 
to occur.[16, 17] The complex of EPAC1, PKA, mAKAP, PDE4D3 and ERK5 was 
found in neonatal cardiomyocytes [18].  
Physiological functions of EPAC 
x Cardiac Function: 
- PKA is involved in cardiac contractility, relaxation and automaticity 
leading to studies on the role of EPAC in cardiac function [19, 20].  
- Mice in which Phospholipase C (PLC) H was knocked out showed a 
decrease in E-adrenergic receptor (EAR)-dependent cardiac contraction. 
PLCH is downstream of EPAC and is the Rap effector [21]. 
- EPAC inhibits TGFE and adenosine-2 receptor induced collagen 
synthesis required for profibrotic response in cardiac fibroblasts [22, 23].  
- Connexin43 that is required for gap junction assembly is recruited by 
EPAC via Rap1 [24]. Stressed mice expressed higher levels of EPAC1 
leading to cardiac hypertrophy, confirming the role of EPAC in cardiac 
function and in disease [25]. 
x Insulin Secretion: 
- Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) 
are released from gastrointestinal cells in response to glucose, which 
stimulates cAMP production from pancreatic beta cells. This process was 
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first thought to be mediated by cAMP on PKA but it was later found that 
EPAC2 was required for the complete induction of insulin under the GLP-
1/GIP stimulation [26, 27].  
- Rim2 (a Ca2+ tether) and Piccolo (a Rim2 interacting protein) interact 
with EPAC2 to prime vesicles required for insulin secretion [27-29].  
- EPAC2 and sulfonyl urea receptor 1 interact leading to the exocytosis of 
insulin through the inhibition of K+ATP channels causing membrane 
polarization and influx of Ca2+[30]. 
Due its role in insulin production, EPAC is implicated in the etiology of 
diabetes and other metabolic disorders.  
Cell adhesion: 
Through interaction with Rap, EPAC activates the lymphocyte function 
associated antigen 1, the very late activation antigen 4 and the 
macrophage integrin 1 that are required for integrin-mediated cell 
adhesion and E-cadherin mediated cell-cell junction formation [31-40].  
8-pCPT-2'-O-Me-cAMP (8CPT) an EPAC specific activator was 
synthesized by the Bos laboratory in 2002. This activator activated EPAC 
and not PKA, thus providing an extremely useful pharmacological tool 
that could be used to the study PKA-indepent effects of cAMP [41]. 
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8CPT allowed determination of the specific role of EPAC1 along with 
Rap1 in E1-integrin-mediated adhesion. This process was cAMP 
dependent and PKA independent.  
Cell permeability induced by 8CPT was decreased by the knockdown of 
EPAC1 or inhibition of Rap [42]. Similar results were also observed in 
vascular endothelial cadherin null cells confirming that the EPAC 
activator is unable to bring about cell permeability in the absence of 
vascular endothelial cadherin [43]. EPAC stimulation has the ability to 
increase cortical actin through the down regulation of Rho [42, 43].  
Role of EPAC in Cancer: 
EPAC was discovered in 1998, and the potential role of this cAMP activated 
protein is being studied in cancer. EPAC has been implicated in cancer 
angiogenesis, DNA damage repair, invasion and migration. cAMP is heavily 
involved in myriad cancer processes, thus implying the importance of EPAC in 
cancer.  
¾ Lung Cancer 
Cho and colleagues determined that stimulation of EPAC1 led to a 
decrease in the DNA damage repair protein - x-ray repair cross 
complementing 1 and the related DNA damage apoptosis in lung cancer 
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[44]. However, Pullamsetti and colleagues demonstrated that 
phosphodiesterase 4 (PDE4) – which hydrolyzes cAMP, has the ability to 
decrease hypoxia inducible factor (HIF) in lung cancer cell lines. This was 
further confirmed by activation of EPAC [45].  
Thus, we see  pro- and anti- tumor effects of EPAC in lung cancer, 
demonstrating the need for further studies of the EPAC isoforms and their 
roles in tumorigenesis and metastasis.  
¾ Melanoma 
Narita et al., demonstrated that both the inhibition of PDE4 and 
stimulation of EPAC promoted melanoma cell growth [46]. The 
Baljinnyam laboratory has done extensive work on the functions of EPAC 
in melanoma and have shown that EPAC promotes translocation of 
syndecan-2, a cell surface heparin sulphate (HS) proteoglycan, which 
causes an increase in melanoma cell migration. Higher levels of EPAC 
were found in metastatic melanoma than in the primary melanoma and 
thus an increased effect on HS in metastatic versus primary tumor [47]. 
They have also shown that EPAC stimulation increases melanoma 
migration by increasing intracellular Ca2+ via the phospholipase-
C/inositol 3 (PIP3) receptor pathway that leads to increased actin assembly 
[48]. The laboratory also showed that melanoma cells with higher 
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expression of EPAC1 control the melanoma/melanoma as well 
melanoma/endothelial cell communication through fibroblast growth 
factor-HS interaction [49].  
¾ Ovarian Cancer 
Studies on EPAC in ovarian cancer are at the nascent stage. EPAC 
activation of gonadotropin stimulated human ovarian surface epithelial 
cells resulted in an increase of epidermal growth factor receptor signaling 
through ERK1/2 and AKT [50]. However, in ovarian cancer ES2 cells, 
treatment with norepinephrine decreased migration activity through 
EPAC activation of phospholipase C enzymes [51] Although there is 
conflicting data regarding EPACs in ovarian cancer, its role cannot be 
overlooked.  
¾ Breast Cancer 
In breast cancer, EPAC activation leads to the inhibition of leptin (an 
important mediator of obesity). This resulted in a decreased leptin 




¾ Prostate Cancer 
EPACs inhibit the proliferative and migratory characteristics of prostate 
cancer cells. These effects are medited through mitogen activated protein 
(MAP) kinase and RhoA pathways [53]. EPAC upregulates the B-Raf 
(isoform of Raf1)/ERK and mammalian target of rapamycin (mTOR) 
pathways to promote prostate cancer cell proliferation [54]. Though both 
studies contradict each other, EPACs appear to play a role in the 
progression of prostate cancer.  
¾ Pancreatic Cancer 
Pro- and anti-tumor effects of EPAC have been reported in pancreatic 
cancer. In one study, elevated levels of cAMP, through EPAC activation 
caused a decrease in migration [55]. However, other studies suggest that 
inhibition of EPAC through selective inhibitors decreases migration and 
eventual progression of the disease. 
EPAC1 is overexpressed in pancreatic cancer [56]. Epac specific inhibitor 
(ESI) – 09, that selectively inhibits EPACs 1 and 2, decreased pancreatic 
cancer cell invasion and migration. This was possible through the 
activation and regulation of integrin E1.  This drug exhibited in-vivo 
effects by inhibiting pancreatic cancer cell metastasis. Mice with tumors 
13 
 
from pancreatic cancer cell lines, when treated with ESI09, exhibited a 
decrease in metastasis to the liver as compared to the controls [57, 58]. 
¾ Colorectal Cancer (CRC) 
So far there have been no reported studies examining the role of EPAC in 
CRC. However, the oncomine database study indicates that EPAC 

















Figure 3: Oncomine data indicating the increase of EPAC expression as 
















Transforming Growth Factor (TGF) E Signaling Pathway:  
CRC is the third most common cancer in the United States and the third most 
fatal in both men and women. In 2014, there were 136,830 new cases of CRC and 
50,310 resulted in death. Individuals who have adenomatous polyps diagnosed 
in their life have a higher risk of developing CRC and one-third of those 
diagnosed with CRC will develop metastatic disease. The death rate from CRC 
has decreased over the years because of regular screenings [59]. However, there 
are no effective treatments for metastatic disease. Morever, patients who present 
with advanced disease are in danger of relapsing with disseminated disease.  
A number of genetic changes occur in the colon for the development of full-
blown cancer from a polyp and the development of metastatic disease. Changes 
in genes such as adenomatous polyposis coli (APC), V-Ki-ras2 kerstin rat 
sarcoma oncogene homolog (Kras), Smad4 and TGFE receptor II (TGFERII), 
phosphatidyl inositol-4,5-bisphosphate 3-kinase alpha (PIK3Ca), phosphatase 
and tensin homolog (PTEN), tumor protein 53 (TP53) and Bax are all 
documented to play a role in the development and progression of CRC [60].  
Activins, inhibins, bone morphogenetic proteins, growth differentiation factors, 
anti-mullerian hormone, glial cell line-derived neutrotrophic factors and the 
TGFE subfamily are part of the TGFE superfamily [61]. TGFE has 3 isoforms - 
TGFE1, 2 and 3 and their function is predominantly growth inhibitory in 
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epithelial cells. The TGFE family also plays an important role in wound healing, 
angiogenesis, cell proliferation, fibrosis and cancer progression [61, 62]. The 
TGFE1 isoform is the most expressed and is usually referred to as TGFE.  
TGFE binds to the TGFE receptor II (TGFERII) which autophosphorylates itself.  
This causes the recruitment and transphosphorylation of TGFERI. TGFERI then 
phosphorylates receptor-activated Smads (Smads 2 and 3) that then associates 
with the Co-Smads - Smad4. The Smad complex then translocates into the 
nucleus where it activates downstream signaling by interacting with promoter 
regions of target genes. This TGFE signaling pathway is called the canonical 






















The Brattain laboratory, in 2011, discovered a non-canonical, TGFE mediated, 
cAMP independent, Smad3 dependent pathway that was able to regulate cell 
survival in CRC [63]. In this pathway, TGFE activated Smad3 through TGFE 
receptor binding. After its activation, Smad3 would bind to PKA, anchored by A-
kinase anchoring protein (AKAP) 149 scaffolding protein. PKA activation by 
Smad3 mediates TGFE repression of survivin and XIAP. Upon cellular stress, 
survivin and XIAP are released from the mitochondria and in the cytosol, they 
heterodimerize to inhibit caspase activation. Activated PKA phosphorylates 
survivin on Ser20 that leads to loss of formation of XIAP and survivin complex 
that protects these IAPs from proteosome degradation and leads to loss of 
caspase inhibition.  The resulting caspase activation leads to apoptosis.  
Smad3 activated PKA also phosphorylates protein phosphatase 2A (PP2A) 
resulting in increased dephosphorylation of protein kinase B (AKT) on Ser473. 
This inactivates AKT and prevents XIAP phosphorylation on Ser87, required for 
binding to survivin again leading to ubiquination and degradation by the 















Protein kinase A (PKA) 
As noted above, PKA is one of the main effectors of cAMP and plays a central 
role in the TGFE non-canonical pathway. PKA is an inactive tetramer of 4 
subunits – 2 regulatory (R) and 2 catalytic (C). When cAMP binds to the 2 
catalytic units, the 2 regulatory units are released and PKA can phosphorylate 
various molecules. Four different genes encode the regulatory subunits. These 
are PKARID, PKARIE, PKARIID and PKARIIE. Each of these units vary in 
cellular distribution as well as in functionality.  
PKARID is ubiquitous while PKARIE is found in the brain, testis and the B- & T-
lymphocytes. Both of these subunits are found in the cytoplasm and are 
associated with cell growth and proliferation. PKARIID is ubiquitously 
distributed but PKARIIE is found in the brain, adipose and in endocrine tissues. 
They vary in their expression in the cell being distributed within different 
subcellular organelles as well in the cytoplasm. The RII subunits are responsible 
for a marked increase in cell differentiation and a decrease in proliferation [64]. 
Differential binding to AKAP accounts for the differential distribution of the 
subunits in the cell [65].  
In cancer, an overexpression of PKARI isoforms has been observed compared to 
the PKARII isoforms. PKARI is usually associated with increased proliferation 
and tumor formation while PKARII is found in growth-arrested cells [66-68]. 
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They are involved in apoptosis through the MDM2/Bcl2 pathway and cause cell 
growth arrest through the Ras/MAPK & Shh/Gli pathways and have the ability 
to remodel the cytoskeleton of the cancer cell [69].  
The Brattain laboratory has demonstrated that PKA can be activated through 
cAMP independent, Smad3 dependent means [63]. cAMP independent activation 
of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-NB) – where 
PKACD associates with inhibitor of NB (I-NB) to form an NF-NB-I-NB-PKACD 
complex in the inactive state, has also been observed. Upon degradation of I-NB, 
PKACD is released and NFNB is activated [70].  
Protein kinase B (AKT) 
AKT is a serine-threonine kinase that has 3 isoforms - AKT1, AKT2 and AKT3. 
All three isoforms are activated by phosphorylation at their highly conserved 
Thr308 and Ser473 by PDK1 and mTORC1, respectively [71].  
AKT1 (PKBD) is more ubiquitous found in the brain, heart and lungs and is 
essential for cell growth and survival [72, 73]. It is found in the cytoplasm and is 
overexpressed in many cancers, playing a role in cell proliferation in gastric 
cancer [74].  
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AKT2 (PKBE) is found primarily in the skeletal muscles and plays a role in 
insulin secretion [75, 76]. It plays a role in cell migration and recently has been 
implicated in metastasis of breast, ovarian and colon cancer [72, 77, 78].  
AKT3 (PKBJ) is mostly found in the brain, kidney and embryonic heart and is 
localized on the nuclear membrane within the cell [79, 80]. It has been implicated 
to play a role in DNA repair in breast and prostate cancer [76].   
The different isoforms of AKT have their docking sites on phosphatidylinositol 3-
kinase (PI3K) that constitutes a major pro-survival pathway that is frequently 
activated in cancer. PI3K converts to phosphatidylinositol-4,5-bis phosphate 
(PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3) at the plasma membrane. 
mTORC2 and PI3K dependent protein kinases (PDK)1 also dock on PI3K, the 
former being able to phosphorylate AKT on Thr308 and Ser473, activating it.  
XIAP 
XIAP is an IAP found on the X-chromosome and contains 3 BIR domains, 1 of 
which binds to caspase 3 & 7 and the other to caspase 9. It also has the (ubiquitin 
associated) UBA domain and a RING finger domain through which XIAP is able 
to ubiquinate and degrade caspase 3 & 7 [81]. The cells’ normal function of XIAP 
is associated with its release from the mitochondria to the cytosol but it also has a 
nuclear function where it inhibits apoptosis by binding to tumor necrosis factor D 
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(TNFD) receptor associated factor (TRAF) 1 & 2[82]. XIAP is known to inhibit the 
intrinsic Bcl2 pathway too [83]. It has the ability to induce NF-NB and thus inhibit 
cell death. XIAP has the ability to form a complex for another IAP – survivin 
leading to poor tumor outcomes by inhibiting caspases.  
Overexpression of XIAP is associated with enhanced chemoresistance [84], while 
whole mouse XIAP knockout was non-toxic and restored chemosensititivity [85, 
86]. Smac memetic peptides [87, 88], Embelin [89-91] and AEG35156 (antisense 
oligonucleotide) [92, 93] are some of the recent strategies used to inhibit XIAP in 
different cancer, none of which have been effectively translated into treatment 
therapies. (Figure 6) 
Survivin 
Survivin is a unique molecule found mostly in the proliferating cells of intestinal 
crypts and is otherwise barely detectable in normal or benign tissues but is 
overexpressed in many cancers including lung cancer [94], osteosarcoma [95], 
oral squamous cell carcinoma [96], breast cancer [97] and thyroid cancer [98].  
Survivin is the smallest member of the IAP family and is encoded by the 
baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) gene and has three 
splice variants [99, 100]. Unique to IAPs, it contains one baculoviral IAP domain 
and requires interaction with XIAP to inhibit casapases.  
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There is a direct relationship between an increased presence of survivin (usually 
during the G2/M phase of the cell cycle) and cancer related death because it has 
the ability to inhibit apoptosis in the both the intrinsic and extrinsic pathways 
[101, 102]. This increased expression is also associated with poor prognosis, high 
risk of relapse and resistance to therapy [103-105]. [106]Survivin is also known to 
suppress radiation induced apoptosis [106-108].  
Survivin forms a complex with XIAP which inhibits caspases and this complex is 
responsible for promoting survival and metastasis [109-111]. Since its presence is 
high in tumor cells versus normal, survivin appears to be a promising 
therapeutic target [112].  
Drugs such as YM155 and FL118 are small molecule inhibitors that are capable of 
suppressing survivin promoter activity [113-115]. Gene therapy was a newly 
developed method to inhibit survivin which included using a dominant negative 
survivin where certain amino-acid mutant substitutions in survivin (Cys84 to Ala 
in the BIR domain) led to the development of a survivin molecule that acts as a 
competitive antagonist to the survivin found normally in the tumor cells. This 
therapy has led to decreased tumor growth through increased cell death in 
breast, thymic lymphoma and gastric cancer cells [116-118]. Development of 
survivin antisense oligonucleotides such as LY2181308 and SPC3042 has allowed 




Survivin is usually localized in the mitochondria and upon cellular stress, is 
released from the mitochondria into the cytosol where it complexes with XIAP 
[109, 122]. Survivin is able to bind to all 3 BIR domains of XIAP and stabilize it. 
PKA has the ability to prevent this association by phosphorylating survivin on 
serine20. The complex prevents XIAP from getting ubiquinated and destroyed 
allowing XIAP to promote cell survival by inhibiting caspases. This complex 
formation also protects survivin, since XAF-1 (XIAP associated molecule) has the 
ability to polyubiquitinate survivin, targeting it for degradation by the 












Figure 6: Domain structure of inhibitor of apoptosis (IAP) proteins – X-linked 














Figure 7: XIAP and survivin form a complex in the cytoplasm that is 
cytoprotective to the cancer cells. The complex prevents XIAP from getting 
ubiquinated therefore promoting cell survival by inhibiting caspases. The 
XIAP-survivin complex also functions to protect survivin from degradation. 








Rationale for our study 
cAMP plays an essential role in a of myriad cell functions like proliferation, 
differentiation and apoptosis. These functions were initially thought to be carried 
out solely by PKA. However, it became clear that various functions of cAMP 
were contradictory and PKA independent. With the discovery of EPAC, some of 
these contradictions were solved because EPAC can work antagonistically or 
agonistically with PKA [4].  
Previous work in our lab on the TGFE/PKA transduceome has demonstrated that 
the cAMP independent, Smad3 dependent activation of PKA led to a decrease in 
XIAP and survivin expression and an overall decrease in cell survival in CRC 
(apoptosis). However, there are no studies on the function of EPAC in CRC [63].  
Oncomine data reveals that expression of EPAC1 and EPAC2 increases with 
progression from adenoma to carcinoma. This lead us to hypothesize that EPAC 
may antagonize PKA function in CRC and maybe responsible for the pro-tumor 
effects of cAMP in this disease.  
Work done in the Brattain Laboratory with the EPAC specific activator (8CPT) 
showed an increase in the phosphorylation of AKT, and an increase in XIAP and 
survivin expression. (unpublished data) Thus, we confirmed that EPAC and 
PKA are acting antagonistically and the pro-survival effect observed on EPAC 
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activation is specifically through EPAC and not PKA [123-125]. This implicates 
EPAC as a potentially important therapeutic target in cancer.  
CRC is the third most common and fatal cancer in the United States. The 
statistics are even worse for pancreatic cancer (PaCa) because of its late detection 
[59]. Therefore, there is a need to develop new therapies that provide benefits in 
the treatment of advanced stage cancer and we hypothesize that EPAC may 
represent such a target.  
Inhibitors of EPAC are useful because EPAC has the ability to interact with the 
TGFE pathway and its inhibition would repress XIAP and survivin as well as 
enhance the inhibitory effects of cAMP activated PKA on cell proliferation.  
Despite the research done on EPACs over the last few years, contributions of the 
specific EPAC isoforms to cancer are only now being addressed. To understand 
these roles, EPAC specific inhibitors (ESI) 05, ESI09 and CE3F4 are some of the 
drugs that have recently been developed.   
EPAC as an epigenetic regulator:  
A recent study demonstrated that cAMP signaling, through an EPAC1-mediated 
inhibition of p38 MAPK, decreased the levels of histone acetyltransferase, p300 
by ubiquinating it in the proteasome in lung cancer cells [126]. p300 HAT 
acetylates histones opening up the chromatin structure allowing for gene 
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transcription. This led us to question if EPAC represses p300 and, if so, is this 
accompanied by an increased expression of HDACs that deacetylate, acetylated 
histones. In both CRC and PaCa, an overexpression of histone deacetylases 
(HDACs) is associated with poor prognosis and death. We will therefore test the 
hypothesis that EPAC is an epigenetic regulator affecting cell survival in 
cancer.  
EPAC activation caused an efflux of HDAC4 and HDAC5 from the nucleus 
confirming an epigenetic relationship between them [127, 128]. This nuclear 
efflux is EPAC specific and was not observed with PKA activation confirming a 
relationship between EPAC and HDACs [129]. Previous work in our laboratoy 
has shown that the pan-HDAC inhibitor, Belinostat, causes an induction of 
tumor suppressor gene - TGFERII through survivin repression [60]. We believe 
that EPAC inhibition would lead to an eventual abrogation of HDAC activity as 
seen with the pan-HDACi’s - causing a decrease in cancer cell survival.  
Histone Deacetylases (HDACs) 
Histone modifications determine chromatin structure. Acetylation of the H-amino 
of lysines confers negative charge opening up the DNA allowing for 
transcription. In contrast, deacetylation results in closed chromatin configuration 
and transcriptional repression [130, 131]. HDACs are classified into 4 main 
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classes – Classes I, II, III and IV. Of these, the class III HDACs are called sirtuins 
and require Nad+ for their activity while the other classes require a Zn2+ cation 
for their function. There are a total of 11 HDACs plus sirtuins that comprise the 
HDAC family [132, 133]. (Figure. 8)  
Of particular interest to our study are Class II HDACs that are further divided 
into Class IIa and IIb. Class IIa includes HDAC4, 5, 7 and 9 while class IIb 
includes HDAC6 and 10. Class IIa HDACs are unique in that they have a 
conserved binding site for transcription factor myocyte enhancing factor (MEF) 2 
as well as 14-3-3 binding sites where there are multiple serines that get 
phosphorylated and allow the HDACs to shuttle between the nucleus and 
cytoplasm. 14-3-3 has a deacetylase domain for its catalytic activity towards the 
C-terminal [134].  
Histone Deacetylase4 (HDAC4)  
HDAC4 is a Class II HDAC that is found exclusively in the brain and growing 
areas of the skeleton in normal cells [135, 136]. HDAC4 is mutated in breast 
cancer and melanoma and its inhibition reduces cancer cell survival [137-141]. 
HDAC4 is overexpressed in several cancers [142, 143]. HDAC4 is also able to 
bind to HIF1-D thus protecting it from degradation and favoring tumor 
progression under hypoxic conditions [144, 145]. Wilson and colleagues 
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confirmed that HDAC4 promotes colon cancer cell growth through the 
repression of p21 [146]. (Figure 9)  
Histone Deacetylase5 (HDAC5) 
HDAC5 is found exclusively in the muscles, heart and brain in normal tissue 
[135, 147, 148]. The role of HDAC5 cancer hasn’t been studied in-depth yet but 
there is increased expression in medullablastomas [149]. HDAC5 inherently 
plays an important role in normal angiogenesis but this role in cancer 
progression has not been studied. In pancreatic cancer, oxysterol binding 
protein-related protein 5 (associated with poor prognosis) is indirectly 
stimulated by HDAC5 [150]. (Figure 9)  
Relationship between EPACs and HDACs 4 and 5 
PKA is known to cause the influx of HDAC4 into the nucleus while EPACs cause 
an efflux of HDAC4 into the cytoplasm [129]. EPAC activation caused HDAC4 to 
efflux from the nucleus into the cytoplasm (in a Ras-dependent signaling 
pathway) while HDAC5 did not. However, in the presence of HDAC4, HDAC5 
was more responsive to EPAC stimulation [127, 128, 151, 152]. This confirms a 
closer relationship between EPAC and HDAC4 than HDAC5.   
The EPAC1/Rap1/CamKI/HDAC5 complex is involved in the placental cell 
fusion, further supporting a relationship between EPAC1 and HDAC5 [153, 154]. 
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Pereira and colleagues, in 2015, showed that EPAC1 was more localized in the 
nuclear envelope of cardiomyocytes while EPAC2 was present in abundance in 
the Z-lines of these cells. On knocking out EPAC1, the nuclear export of HDAC5 
was abrogated [155].  
These studies point to a relationship between EPAC activation and HDAC 4 & 5 
regulation but it has yet to be determined whether this relationship exists in 



























Figure 9: HDACs 4 and 5 belong to Class IIA and have 1084 and 1122 amino 
acids, respectively. They contain a long N-terminal adaptor domain – green 
rectangles are for the myocyte enhance factor (MEF) binding site; turquoise 
circles indicate where chaperone protein 14-3-3 binds and is labeled with S – 
serine phosphorylation; while the asterisks indicate nuclear localization 













Challenges in studying EPACs: 
x Unlike PKA that has a direct assay to measure its activation there is no 
direct assay to measure EPACs. The only assay that exists measures Rap-
GTP levels which precludes analysis of any functions of EPAC that are 
independent of Rap.  
x There is a lack of specific antibodies to EPAC1 and EPAC2 and this makes 
quantification of protein expression difficult. We have a developed an IP 
protocol to help circumvent these difficulties. EPAC mRNA is readily 
quantifiable but this does not directly provide information of protein 
expression or post-translational modifications that may affect activity. 
The best available tool is an EPAC specific activator - 8CPT- that was only 
developed in 2003, after the discovery of EPACs in 1998. This activator is specific 
to EPAC because it contains a methyl group near the catalytic binding site that 
makes it too large for interaction with PKA’s cAMP binding site. Previous work 
done in our laboratory has shown that EPAC activation with 8CPT causes an 
increase in cancer cell survival through an increase in XIAP, survivin and 
phosphorylation of AKT. Other EPAC activator analogues have recently been 
reported, these are the sulfonylureas – Tolbutamide, Glibendamide and 
Glicazide. These activators are specific for EPAC2 and are able to bind to the 
CNB domains [41, 147, 156-159]. However, they are not commercially available.  
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Tsalkova and colleagues in 2012 developed an EPAC specific inhibitor (ESI). 
ESI05 selectively inhibits EPAC2 by binding to its CNB domain [160]. ESI09 
inhibits both EPAC1 & 2 and it does this by competing with cAMP for the CNB 
domain on EPAC as well as inhibiting the GEF activity in both isoforms [57, 58, 
159].  
A new inhibitor, CE3F4, has recently been developed that inhibits EPAC1 
specifically. This racemic drug exerts its inhibition allosterically – by binding to 
cAMP bound EPAC1 which is in the open conformation [161]. The Courilleau 
laboratory also confirmed in 2013 that the R-enantiomer has 10-fold more 
selectivity towards EPAC1 than the racemic mixture [162]. 
For the purpose of my study, we will be examining the roles played by ESI09 
(EPAC1 and 2 inhibitor), ESI05 (EPAC2 inhibitor), and CE3F4 (EPAC1 inhibitor) 
in decreasing XIAP and survivin and overall cell survival in both colon and 







Materials and Methods 
Cell culture and Reagents: 
CRC cell lines were derived from patient tumors and grown in serum free (SF) 
medium that contains Supplemental McCoy’s 5A (Sigma Aldrich), 5ng/ml 
epidermal growth factor (EGF) (R&D Systems), 20µg/ml insulin (Sigma) and 
4µg/ml transferrin (Sigma). 
The FET cell line is non-tumorigenic and retains low levels of TGFE signaling. 
The CBS cell line retains metastatic capability. The CBSRII colon cancer cell line 
was made in our laboratory using a stable transfection of the overexpression 
vector of TGFERII gene with neomycin selection vector into parental CBS cells. 
These same parental CBS cells without the TGFERII gene inserted were named 
CBSNeo. Due to epigenetic silencing of TGFERII in the parental CBS cell lines, 
the CBSNeo cell line is resistant to growth inhibition by TGFE [163, 164].  
The pancreatic cancer cell lines Miapaca, Capan, CFPAC and T3M4 were all 
cultured in 10F medium which contained Supplemental McCoy’s 5A 
supplemented with 10% FBS. Miapaca and T3M4 retain wild-type Smad4, Capan 
has mutant Smad4 and CFPAC is Smad4 null.  
All cell lines were grown and incubated at 37qC in a humidified atmosphere of 
6% CO2.  
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8CPT was obtained from Sigma Aldrich. ESI09 and ESI-05 were purchased from 
Biolog. LMK235 was purchased from Selleck. The racemic mixture of CE3F4 was 
first obtained from Dr. Courilleau’s lab in France and since then the racemic 
mixture, and the R & S enantiomers individually were synthesized by the Amar 
Natarajan Lab at the University of Nebraska Medical Center, Omaha, NE. 
Western Blotting and Immunoprecipitation:  
Colon cancer as well pancreatic cancer cells were plated and treated on day 3 and 
day 2, respectively. Cells were washed 3 times with cold phosphate buffer saline 
(PBS) that contains 0.1% EDTA. Washed cells were scraped and lysed with 
TNESV buffer [50mmol/L Tris (Ph 7.5), 150mmol/L NaCl, 1% NP40, 50mmol/L 
NaF, 1mmol/L Na3VO4, 25μg/ml β-glycerophosphate, 1mmol/L 
phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor cocktail 
(Roche,Indianapolis, IN)]. Cells were lysed using a syringe, after 30min 
incubation with the lysis buffer and centrifuged at 14000g’s for 20min at 4qC. The 
supernantant was extracted and protein in it was quantified using the 
bicinchoninic acid(BCA; Pierce). The protein was diluted in SDS sample buffer 
(50mM Tris, ph 6.8, 1% SDS, 10% glycerol, 0.03% bromophenol blue and 1% β-
mercaptoethanol) and separated by SDS-PAGE (7.5-15% gels). The gels were 
then transferred by electroblotting (100V for 90min or overnight at 10V at 4°C) 
onto a nitrocellulose membrane (GE Amersham). Post transfer, the membrane 
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was blocked with 5% non-fat dry milk in TBS-T (150mmol/L NaCl, 10mmol/L 
Tris-HCl pH7.4, 0.05% Tween 20) for 1hr at room temperature or overnight at 
4°C.  The membrane was cut at requisite molecular weights and primary 
antibody was added in either 5% non-fat dry milk or 5% bovine serum albumin 
(BSA) in TBS-T for 2hr at room temperature or overnight at 4°C according to the 
antibody data sheets.  The membrane was washed three times for 10min in TBS-T 
and the appropriate secondary was added in 5% non-fat dry milk for 1hr at room 
temperature. The membrane was washed three more times with TBS-T for 10min 
at room temperature and the proteins were detected by the enhanced 
chemiluminescence system (ECL; GE Amersham). Immunoprecipitation was 
performed with 500μg of protein samples using agarose beads (Santa Cruz) 
according to manufacturer’s protocol and previously established method. 
(Howell 2011) Survivin (#2808), XIAP (#14334), and HDAC4 (#5392) were 
purchased from Cell Signaling. EPAC1 (sc-28366) was purchased from Santa 







MTT and DNA Fragmentation:  
The colon cancer cell lines, FET, CBSNeo and CBSRII were seeded at 5,000 cells 
per well and pancreatic cancer cell lines - Miapaca (4000 cells/well), Capan (5000 
cells/well), CFPAC (4000 cells/well) and T3M4 (4000 cells/well) in 96 well plates 
for MTT and DNA Fragmentation.  Three days following plating, colon cancer 
cells were treated for the specified times and MTT/DNA Fragmentation assays 
were performed on day 5.  Pancreatic cancer cells were treated 2 days after 
plating and assays began on day 4. 50µl of the 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution from Sigma was added to each 
well to the existing media and incubated at 37°C for 2hr. The solution from each 
cell was aspirated – which stopped the reaction and 100µl of di-methy sulfoxide 
(DMSO) was added to each well and followed by shaking for 15mins at room 
temperature, covered in foil. Absorbance was read at 570nm using a 96-well plate 
reader.   
The second 96-well plate was used to assess apoptosis.  DNA fragmentation was 
measured using the Cell Death Detection ELISA Plus kit from Roche according to 
the manufacturer’s instructions.  DNA Fragmentation results were normalized to 




Transient transfection:  
On-TARGETplus SMARTpool HDAC4 siRNA was purchased from Dharmacon 
(Thermo Fisher Scientific Inc., USA) and knockdown was performed according 
to the manufacturer's protocol.   
RNA isolation and quantitative real time PCR: 
RNA was collected from treated cells using the High Pure RNA Isolation 
kit (Roche Applied Science) according to the manufacturer's protocol. The 
two-step quantitative PCR using TaqMan reagent was performed 
according to the manufacturer's instructions (Applied Biosystems). The 
mRNA expression was normalized to GAPDH. All probes were purchased 







1. EPAC activation by 8CPT increases cancer cell survival. 
To determine the role of EPAC in CRC we first used 8CPT – EPAC specific 
activator – and examined the effect on cell survival. We hypothesized that 
EPAC would mediate pro-tumorigenic effects of cAMP in opposition to 
the effects of PKA as depicted in the schematic below. 
 
We treated the FET CRC cell line with 8CPT and observed an increased of  
XIAP and survivin proteins by Western blot. (Figure 1.1) FET is a non-
tumorigenic CRC cell line with low TGFE signaling. On treatment with 
8CPT, there was no change in cell proliferation but DNA fragmentation 
decreased confirming that EPAC activation was behaving antagonistically 




Figure1.1:  Treatment of CRC cell line FET with EPAC activator increases cell 
survival associated proteins in a time-dependent manner.  Data shown are 













Figure 1.2: EPAC activation has no effect on cell proliferation but decreases 
DNA fragmentation therefore increasing cell survival in CRC cell line – FET. 















2. Inhibition of EPAC1 and EPAC2 by ESI09 decreases cell survival. 
The EPAC activator activates both EPAC1 and 2 isoforms. In order to 
begin to dissect out the roles of the specific EPACs, we utilized the newly 
developed EPAC specific inhibitors.  
As EPAC activation results in an increased expression of survivin and 
XIAP, we hypothesized that EPAC inhibition would inhibit cell suvival 
and therefore represent a potential therapy for cancer.  
We treated the CRC cell lines - FET (weak TGFE signaling; non-
metastatic), CBSNeo (no TGFE signaling; highly metastatic) and CBSRII  
(functional TGFE signaling, poorly metastatic) as well as PaCa cell lines – 
Miapaca (Smad4 wildtype), Capan (Smad4 mutant), CFPAC (Smad4 null) 
and T3M4 (Smad4 wildtype) with ESI09 – selective inhibitor of EPAC1 
and 2 which resulted in a decrease in cell proliferation as observed in the 
MTT assay as well as an increase in cell death as observed in the DNA 
Fragmentation Assay. Western Blot analysis of IAP proteins XIAP and 
Survivin showed a decrease as well.  
Q-RTPCR results of XIAP and survivin on treatment with ESI09 showed a 




Figure 2.1: ESI09 (1um) decreased cell proliferation and increased DNA 
fragmentation in the FET CRC cell line. Data shown are representative 


















Figure 2.2: Treatment of the 3 CRC cell lines with 1um of ESI09 caused a time-
dependent decrease in IAP proteins confirming that EPAC inhibition causes a 
decrease in cancer cell survival. Data shown are representative of three 







Figure 2.3a: Treatment of Miapaca cell line with ESI09 decreased cell 
proliferation and increased DNA fragmentation. Data shown are 







Figure 2.3b: Western blot analysis of the treatment of Miapaca with 
ESI09 demonstrated a decrease in IAP proteins thus decreasing cell 











Figure 2.3c: Treatment of Miapaca with ESI09 decreased IAP molecule 
survivin at the mRNA level both at 24 and 48hrs. Data shown are 











Figure 3.a: Treatment of CFPAC cell line with ESI09 decreased cell 
proliferation and increased DNA fragmentation. Data shown are 





Figure 3.b: Western blot analysis of the treatment of CFPAC with ESI09 
demonstrated a decrease in IAP proteins thus decreasing cell survival. Data 







Figure 3.c: Treatment of CFPAC with ESI09 decreased IAP protein Survivin at 











Figure 4.a: Treatment of Capan cell line with ESI09 decreased cell 
proliferation and increased DNA fragmentation. Data shown are 







Figure 4.b: Western blot analysis of the treatment of CAPAN with ESI09 
demonstrated a decrease in IAP proteins thus decreasing cell survival. 










Figure 4.c: Treatment of Capan with ESI09 decreased IAP molecule 
survivin at the mRNA level both at 24 and 48hrs. Data shown are 













            
Figure 5.a: Treatment of T3M4 cell line with ESI09 decreased cell proliferation 
and increased DNA fragmentation. Data shown are representative of three 







Figure 5.b: Western blot analysis of the treatment of T3M4 with ESI09 
demonstrated a decrease in IAP proteins thus decreasing cell survival. Data 






Figure 5c: Treatment of T3M4 with ESI09 decreased IAP molecule- 
survivin at the mRNA level both at 24 and 48hrs. Data shown are 










3. EPAC2 selective inhibition cannot inhibit XIAP and survivin. 
ESI09 inhibits both EPAC isoforms. To begin to dissect which isoform is 
involved in cell survival, we utilized ESI05, which inhibits EPAC2 
selectively. ESI05 binds the hinge region of EPAC2 and  prevents cAMP 
binding to the CNB domain. We treated the CRC cell lines - FET (weak 
TGFE signaling; non-metastatic), CBSNeo (no TGFE signaling; highly 
metastatic) and CBSRII  (functional TGFE signaling, poorly metastatic) as 
well as PaCa cell lines – Miapaca (Smad4 wildtype), Capan (Smad4 
mutant), CFPAC (Smad4 null) and T3M4 (Smad4 wildtype) with ESI05 
and observed no change in XIAP and survivin in both the protein and 
mRNA levels. Changes in mRNA levels of ESI05 were compared to that of 









Figure 6: Expression of survivin and XIAP were unaffected in CRC cell lines – 
FET, CBS and CBSRII was treated with ESI05 (EPAC2 selective inhibitor). 
However, when treated with the same concentration of ESI09 (inhibits both 
isoforms) there was a decrease, indicating that EPAC1 could be involved in the 













Figure 7.a: Treatment of Miapaca cell line with ESI05 did not significantly 
change cell proliferation or DNA fragmentation. Data shown are 






Figure 7.b: Western blot analysis of the treatment of Miapaca with ESI05 
demonstrated no change in IAP proteins. Data shown are representative of 






Figure 7c: The Miapaca cell line was treated with ESI05 at 10um at 24 
hours and survivin levels were compared to the ESI09 treatment at the 
same concentration. Compared to ESI09 treated at 10um at 24 hours, 
there is no decrease in survivin in the ESI05 treated under similar 








                                                                                                                           
Figure 7.a: Treatment of CFPAC cell line with ESI05 exhibited no significant 
change in cell proliferation or DNA fragmentation. Data shown are 







Figure 7.b: Western blot analysis of the treatment of CFPAC with ESI05 
demonstrated no change in IAP proteins. Data shown are representative of 








Figure 8c: The CFPAC cell line was treated with ESI05 at 10um at 24 
hours and survivin levels were compared to the ESI09 treatment at the 
same concentration. Compared to ESI09 treated at 10um at 24 hours, 
there is no decrease in survivin in the ESI05 treated under similar 







                                                                                                                           
Figure 9.a: Treatment of Capan cell line with ESI05 exhibited no significant 
change in cell proliferation or DNA fragmentation. Data shown are 






Figure 9.b: Western blot analysis of the treatment of Capan cell line with ESI05 
demonstrated no change in IAP proteins. Data shown are representative of 







Figure 9c: The Capan cell line was treated with ESI05 at 10um at 24 hours and 
survivin levels were compared to the ESI09 treatment at the same 
concentration. Compared to ESI09 treated at 10um at 24 and 48 hours, there is 
no decrease in survivin in the ESI05 treated under similar conditions. Data 








4. EPAC1 selective inhibition represses XIAP and survivin. 
Selective inhibition of EPAC2 produced no detectable effects on cell 
survival in either CRC or PaCa cell lines. Therefore, we hypothesized that 
EPAC1 was the key isoform involved in cell survival. In order to test this 
hypothesis, we utilized the selective EPAC1 inhibitor, CE3F4, that was 
obtained from the Corilleau laboratory in France. They provided us with 
the racemic mixture which was used to treat CRC as well as PaCa cell 
lines.  CE3F4 is an allosteric inhibitor of EPAC1.  
Cell proliferation assays were performed and a maximal effect was 
observed at 50uM. Treatment of the CRC cell lines -FET & CBS with 









Figure 10.1: Treatment of FET CRC cell line with CE3F4 -EPAC1 selective 
inhibitor resulted in a decrease in cell proliferation. CE3F4 is a racemic 
mixture and therefore, responses are observed at higher concentrations. The R-
enantiomer exhibits activity at much lower concentrations. Data shown are 







Figure 10.2: The FET cell line when treated with CE3F4 (EPAC1 selective 
inhibitor) reduces XIAP and survivin expression at 40µm which is the 
IC50 of the racemic mixture of the drug. Data shown are representative of 









5. EPAC inhibition decreases HDACs 4 and 5. 
Jeong et al demonstrated that EPAC activation causes a repression in HAT 
p300. This HAT acetylates histones so we hypothesized that in addition to 
decreasing the acetylating enzyme, EPACs would induce HDACs.  
Therefore, we studied the effect of EPAC inhibition on HDAC expression 
in our CRC cell lines. If EPACs are able to induce HDAC expression, then 
inhibition should decrease expression and potentially be regarded as an 
epigenetic regulator. 
Treatment of our CRC cell lines with ESI09 produced a decrease in 
HDACs 4 and 5. In contrast, the inhibitor produced no effect on HDAC3 
expression and only a slight decrease in HDAC1 expression. These results 
demonstrate that the EPACs exhibit specificity with regards to their effects 








Figure 12a: Treatment of CRC cell lines with ESI09 decreased HDAC4 in 
a dose-dependent manner. Data shown are representative of three 






Figure 12b: Treatment of CRC cell lines with ESI09 decreased HDAC5 in a 









Figure 12.c: Inhibition of the CRC cell lines with ESI09 produced only a slight 
decrease in HDAC1 but no decrease in HDAC3. Data shown are representative 










6. Inhibition of HDAC4 and 5 by LMK235 (selective inhibitor of HDAC4 
and 5) causes a decrease in cell survival. 
The previous studies provide evidence that HDAC4 and 5 expression is 
regulated by EPACs. This raised the question whether the regulation of 
HDAC 4 and 5 was directly involved in the cell survival effects mediated 
by EPAC.  
We therefore hypothesized that if HDAC4 (and 5) are involved in 
mediating downstream signaling of EPACs then HDAC 4 and 5 inhibition 
should recapitulate the effects of EPAC inhibition on cell survival.  
In order to test this, we first used the HDAC4 and 5 inhibitor, LMK235. It 
is selective towards HDAC 4 and 5 in low nanomolecular levels because of 
the way it is able to dock and inhibit the Zn2+ cation required for both of 
these HDACs to function [165]. This drug decreased XIAP and survivin 
expression in both Smad4 wild type and Smad4 mutant (Capan) cells, in a 
concentration dependent manner. This was confirmed through western 
blot as well q-RTPCR.  
We also examined the effect of specific HDAC4 knockdown (KD) on XIAP 





Figure 13a: Treatment of the Miapaca cell line with LMK235 decreases XIAP 
and survivin in a dose dependent manner at both 24 and 48hours. This cell 
survival effect through HDAC4 and 5,  points to a role of EPACs as epigenetic 










Figure 13b: Treatment of the Miapaca cell line with LMK235 decreases 
survivin at the RNA level at 24hours. Data shown are representative of three 











          
Figure 14a: Treatment of the Capan cell line with LMK235 decreases XIAP and 
survivin in a dose dependent manner at both 24 and 48hours. This cell survival 
effect through HDAC4 and 5, points to a role of EPACs as epigenetic 










Figure 14b: Treatment of the Capan cell line with LMK235 decreases XIAP and 
survivin at the RNA level at 24hours. Data shown are representative of three 










        
Figure 15a: Treatment of the CFPAC cell line with LMK235 decreases XIAP 
and survivin in a dose dependent manner at both 24 and 48hours. This cell 
survival effect through HDAC4 and 5, points to a role of EPACs as epigenetic 











 Figure 15b Treatment of the CFPAC cell line with LMK235 decreases XIAP 
and survivin at the RNA level at 24hours. Data shown are representative of 










                            
Figure 16a: Treatment of the T3M4 cell line with LMK235 decreases XIAP and 
survivin in a concentration dependent manner at both 24 and 48hours., 
suggesting the role of EPACs as epigenetic regulators. Data shown are 









 Figure 16.c: Treatment of the T3M4 cell line with LMK235 decreases XIAP and 
survivin at the RNA level at 24hours. Data shown are representative of three 











Figure 17:  siRNA mediated HDAC4 KD decreased XIAP expression in the 










PKA is the traditional effector of cAMP but it has since been discovered that 
many cellular functions like proliferation, migration exocytosis and secretion are 
PKA independent [1, 2, 166]. This opened the field to other cAMP effectors, 
notably the EPACs. Misra and Pizzo in 2009 reported that PKA and EPAC 
functioned antagonistically [54]. Of particular importance was the regulation of 
phosphorylation of AKT – a key survival molecule in cancer that is required for 
the stabilization of the IAP proteins – XIAP and survivin - PKA and EPAC 
function antagonistically in the phosphorylation of AKT. 
Previous work in our laboratory identified a unique TGFβ signaling 
transduceome which exerted its anti-tumorigenic effects in a non-canonical TGFβ 
pathway thorugh the deactivation of AKT and destabilization of XIAP and 
survivin [63]. It does this by activating PKA in a cAMP independent, Smad3 
dependent manner that leads to AKT dephosphorylation through PKA mediated 
PP2A activation and PKA dependent survivin phosphorylation that causes 
destabilization of the XIAP/survivin complex leading to the proteosomal 
degradation of the IAPs.  
EPACs however, promote AKT mediated cancer proliferation in an antagonistic 
fashion as compared to the anti-tumor effects of PKA [54]. EPACs have been 
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implicated in cancer cell migration, invasion and invadopodia formation and 
form part of the TGFβRI interactome [57, 167, 168]. Thus EPACs function 
antagonistically to the inhibitory TGFβ signaling effects observed in cancer cells. 
Previous studies done in our lab using RAPGEF inhibitor, Brefeldin A led to a 
decrease in pAKT, XIAP and survivin in CRC. When treated together with TGFβ 
there was a further decrease in survivin expression.  
Based on these previous findings we hypothesized that EPAC would exert pro-
tumorigenic effects through enhancement of cell survival in opposition to the 
effects of TGFβ and PKA. Initially to test this hypothesis, we utilized the EPAC 
specific activator, 8CPT which could not interact with PKA due to the presence 
of a methyl group. EPAC activation led to increased cell proliferation, decreased 
apoptosis and increased expression of the cell survival proteins survivin and 
XIAP.  The EPAC activator does not distinguish between the two EPAC 
isoforms. Therefore in order to determine which isoforms(s) was mediating the 
cell survival effects, we utilized newly available selective EPAC inhibitors in 
both CRC and PaCa cell lines.  
ESI09 (inhibits EPAC1 and 2), ESI05 (inhibits only EPAC2) and CE3F4 (inhibits 
only EPAC1). We discovered that inhibition of EPACs by ESI09 led to a decrease 
in XIAP and survivin but this effect was not observed in cells treated with ESI05 
– allowing us to hypothesize that EPAC1 is responsible for the pro-survival 
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effects found in cancer. We used the racemic mixture of CE3F4 in CRC cells and 
observed a decrease in XIAP and survivin confirming that EPAC1 indeed was 
connected to the pro-survival role in cancer. We were then able to synthesize the 
different enantiomers of CE3F4 and cell proliferation studies with these 
enantiomers showed a concentration dependent decrease with the R-enantiomer 
compared to the S-enantiomer and the racemic mixture. Identification of EPAC1 
as the isoform responsible for pro-survival effects observed in CRC and PaCa 
cancer was one of the major results from this study. These results identify EPAC1 
as a potential therapeutic target for CRC and PaCa.  
We examined the effect of ESI09 on HDACs. ESI09 treatment led to a decrease in 
HDACs 4 and 5 which led us to hypothesize that EPACs act as an epigenetic 
regulator and cause a decrease in cell survival through the inhibition of these 
HDACs.  
HDACs are overexpressed in many different kinds of cancers. HDAC4 is on 
chromosome 2q37.3 and is involved in neuronal stabilization, bone growth and 
skeletal muscle development. HDAC4 and 5 are Class II HDACs that shuttle 
between the cytoplasm and nucleus. Certain signals will allow HDAC4 to 
interact with 14-3-3 and enter the cytoplasm [169]. Importin is another protein 
that HDAC4 interacts with to efflux from the nucleus into the cytoplasm [170]. 
HDAC4 along with HDAC5 when overexpressed decreased the βcells (produces 
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insulin) and the δcells (produces somatostatin) of the pancreas indicating their 
role in diabetes [171]. HDAC4 directly interacts with tumor suppressor micro-
RNA22 and downregulates it in hepatocellular cancer and inhibiting HDAC4 
increases micro-RNA22 decreasing cell proliferation of hepatocellular cancer 
cells [172]. Platinum chemoresistant ovarian tumors had an increased level of 
HDAC4 compared to the non-chemoresistant tumors [173]. Compared to the 
normal bladder cells, HDAC4 was found at higher levels in the tumor cells [174]. 
HDAC4 is mutated in breast cancer and melanoma [141]. HDAC5 also is 
important in cancer but its role so far appears to be mostly in angiogenesis [175]. 
HDAC5 also regulates PTEN in PaCa and plays a role in cancer cell proliferation 
[149, 150].  
EPAC activation is known to cause an efflux of HDAC4 from the nucleus into the 
cytoplasm. HDAC5 was not responsive to this activation [127]. Activation of 
EPAC also causes a decrease in HAT p300 levels allowing us to hypothesize that 
if EPAC activation is causing a decrease in HAT levels and an increase in HDAC 
levels (efflux from nucleus) then EPAC inhibition must cause a decrease in 
HDACs, therefore EPAC behaves as an epigenetic regulator.  
Inhibition of EPACs by ESI09 caused a decrease in the levels of HDAC4 and 5.  
Of importance is the relationship between HDAC4 and hypoxia inducible factor 
1-α (HIF1-α). HIF1-α is part of the hypoxic response that is found in most solid 
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tumors and is responsible for the generation of survival pathways by 
upregulating protein responsible for angiogenesis and anaerobic metabolism 
[176-178].  
Inhibitors of HIF-1α or circumstances that can mitigate it may be beneficial in 
many solid tumors. ESI09 causes a decrease in HDAC4 and 5 – of importance to 
this study is the decrease in HDAC4.  
HDAC4 regulates HIF1-α’s acetylation and stability because it directly interacts 
with HIF1-α  through its multiple lysines. When HDAC4 and 5 bind to HIF1-α, 
binding of FIH-1 (factor inhibiting HIF1-α) is prevented and association with 
p300 (HAT) is increased – causing increased stability of HIF1-α. Inhibition of 
HDAC4 leads to deacetylation of HIF1-α and eventual degradation because of 
lack of stability in non-small cell lung cancer. Panobinostat (pan-HDAC 
inhibitor) when given in combination with cisplatin exhibited higher levels of 
apoptosis and reduced tumor growth in non-small cell lung cancer. HDAC4 
inhibition was also responsible in the reduction of glycolysis (hypoxia related) 
and chemoresistance to docetaxel [144, 179, 180]. Thus, HDAC4 presents itself as 
an exciting therapeutic target for the treatment of cancer. 
PaCa cell lines when treated with ESI09 (inhibits EPAC1 and 2) showed a 






We inhibited HDAC4 and 5 using the drug LMK235 and observed a decrease in 
XIAP and survivin. Knocking down HDAC4 with siRNA also showed a similar 
effect.  
Thus the inhibition of EPAC plays an important role in cell apoptosis and tumor 
progression. EPAC when inhibited will decrease the levels of HDAC4 and 5 and 
this in turn will cause the destabilization and degradation of HIF1-α. EPAC1 
may represent a therapeutic target and CE3F4 represents a prototype drug to 




1. Synthesize different enantiomers of CE3F4 and treat CRC cells and PaCa 
cells to confirm the role of EPAC1 in the progression of cancer.  
2. Develop stable inducible knockdowns of EPAC1 and 2 and confirm their 
role in cell survival.  
3. Confirm the relationship between HDAC4 and HIF1-α. Perform hypoxic 
studies with a combination of CE3F4 and LMK235.  
4. Generate stable knockdowns of HDACs 4 and 5.  
 
Conclusions: 
EPAC1 enhances pro-survival signaling in CRC or PaCa. My research in this part 
of the dissertation has shown that EPACs, particularly EPAC1 behaves as an 
epigenetic regulator and is able to regulate cancer cell survival. Published 
literature has thus far not shown any relationship between epigenetics and EPAC 
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Colorectal cancer is the 3rd leading cause of cancer deaths in the United States. 
Activation of oncogenes and silencing of tumor suppressor genes (TSG) 
contribute to the development and progression of colorectal cancer. One such 
TSG is the transforming growth factor β receptor II (TGFβRII) which results in 
loss of growth inhibitory TGFβ signaling and is a common event in cancer 
progression. Although mutation of this TSG is common, especially in tumors 
which exhibit microsatellite instability there is increasing evidence that TGFβRII 
is epigenetically silenced in many different cancers.  Restoration of TGFβ 
signaling by re-introduction of TGFβRII results in anti-cancer effects in colon and 
other cancer cell lines.  
Histone deacetylases (HDACs) are involved in the mechanism of epigenetic 
silencing. These enzymes remove the acetyl groups from lysine tails of histones 
usually resulting in gene repression. HDACs are classified into 4 groups (Classes 
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I, IIa, IIb, III and IV) and, except for Class III, need the zinc cation for their 
function. Deacetylation by Class III HDACs (Sirtuins) is NAD+ mediated. Histone 
deacetylase inhibitors (HDACi) have recently entered clinical trials and are 
effective in inhibiting growth and inducing apoptosis in many hematological 
malignancies but results against solid tumors as single therapies has been 
disappointing.  A significant effect of these drugs is reactivation of TSGs via 
histone deacetylation inhibition which results in alterations in the chromatin 
permitting transcription of these silenced genes. 
Our laboratory has previously demonstrated that the pan HDACi Belinostat, 
which inhibits Class I and II HDACs, effectively induced TGFβRII expression in 
cancer cell lines with epigenetically silenced receptor restoring TGFβ 
downstream signaling effects including the TGFβ dependent decrease in 
survivin. Therefore, HDACi provide a potential therapy to restore the growth 
inhibitory and apoptotic effects of the TGFβ inhibitory pathway. We hypothesize 
that the identification of the specific HDACs involved in reactivation of 
epigenetically silenced TGFβRII would allow the use of more specific HDACi’s 
which would increase the therapeutic index of these drugs, decrease side effects 
and permit more effective use in combination therapies.  
We are using both genetic and pharmacological approaches to identify the 
specific HDACs involved in reactivation of TGFβRII. We have performed 
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lentiviral shRNA knockdown of HDAC1, 2 and 3 and observed that KD of 
HDACs 1 and 3 caused the induction of TGFβRII. However knock down of 
HDAC2 had no effect on TGFβRII expression. Treatment of colon cancer cells 
which exhibit epigenetically silenced TGFβRII with the HDACi Mocetinostat, 
specific for the Class I HDACs1, 2, 3 and 11, resulted in robust TGFβRII 
expression. However, treatment with Droxinostat, specific for HDACs 6 and 8, 
and at higher concentrations HDAC3, did not result in TGFβRII induction until 
concentrations effective in inhibiting HDAC3 were achieved. Treatment of colon 
cancer cells with histone methyltransferase inhibitors – UNC0638 and DZNEP – 
G9a and EZH2 inhibitors respective induced TGFβRII. HDAC inhibitors are able 
to induce TGFβRII but also cause a decrease in histone methyl transferases G9a 










Colorectal Cancer (CRC) 
CRC is the the 3rd most common cancer and the 3rd most fatal cancer in the 
United States. According to the American Cancer Society, 136,830 men and 
women were diagnosed with CRC in 2014, out of which 50,310 died from the 
disease. This cancer develops slowly over a period of 5-10years [181]. 
Contributing factors include sedentary lifestyle, obesity and a diet rich in red 
meat but lacking in fresh fruit, vegetables and fiber[182-185]. Regular 
colonoscopies (screening) have improved outcomes with early detection. 
However, 1/3rd of patients diagnosed with CRC have advanced disease with 
metastases or will relapse with metastatic disease. The 5-year survival rate for 
patients with distant metastasis is 12% [186]. There is a need to understand the 
progression of the disease from normal to carcinomas to metastatic disease as 
well as develop therapies that will combat advanced CRC at each step.  
Multiple genetic mutations are responsible for normal colon epithelium to 
develop into a cancerous tissue [187]. (Figure1) Early studies on CRC have 
determined the genetic targets in CRC with the help of 2 inherited syndromes – 
Familial Adenomatous Polyposis (FAP) and Hereditary Nonpolyposis Colorectal 
Cancer (HPNCC) also known as the Lynch syndrome [188-191].  The 
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adenomatous polyposis coli (APC) protein is involved in cell cycle regulation, 
cell death and proliferation and plays a central role in FAP where benign polyps 
develop from the normal colon. Mutation of the APC gene allows for the 
aberrant proliferation of the colon cells. Benign polyps then progress to form 
adenomas and eventually into full-blown carcinomas [192, 193].  
Lynch syndrome occurs when an inherited mutation occurs in the mismatch 
repair genes (MMR) which include – MutL homolog 1 (MLH1), MutS protein 
homolog 2 (MSH2), MutS homolog 6 (MSH6) or postmeiotic segregation 
increased 2 (PMS2) [194]. Insertions or deletion mutations that occur in any one 
of these genes at the nucleotide repeat sequences also known as microsatellites 
cause microsatellite instability (MSI) and this is common in many tumor 
suppressor genes (TSG) like transforming growth factor receptor (TGFβRII) [195-
197]. Around 30% of all tumors in CRC have TGFβRII mutations [198].   
CRC progresses from a benign polyp to an adenomatous polyp. If detected at 
this stage and surgically excised, the patient is rescued from cancer development. 
If not removed, the adenomatous polyp may progress into an adenoma (surgery 
+ chemotherapy), to carcinoma (radiation, surgery and chemotherapy) and 
finally to metastatic disease to other organs in the body. Genes such as APC, K-




Figure 1. Genetic changes in different genes involved in tumorigenesis and 












TGFβ signaling pathway 
TGFβ signaling generates a growth inhibitory pathway that is pivotal in tumor 
suppression in CRC. It has been reported that TGFβ signaling can promote 
tumorigenesis in advanced stages of other cancers, particularly breast cancer 
[204]. However, the Brattain Laboratory has demonstrated that reconstitution of 
TGFβ receptors into cell lines lacking receptor expression inhibits progression 
and metastasis [205].  
The TGFβ family comprises 3 isoforms – 1, 2 and 3, that possess a high degree of 
homology and are part of a family of structurally related proteins such as the 
activins, inhibins, bone morphogenetic factors, growth differentiation factors, 
glial cell line-derived neurotrophic factors and anti-mullerian hormones [62, 206-
209].  The TGFβ1 isoform is the most abundant and is often referred to TGFβ.  
TGFβ functions through the TGFβ receptors I and II (TGFβRI and TGFβRII) that 
are serine threonine kinases [210]. TGFβ binds to TGFβRII and causes it to 
autophosphorylate itself leading to activation of the TGFβ canonical pathway. 
Phosphorylated TGFβRII sequesters TGFβRI and trans-phosphorylates it. 
TGFβRI in turn phosphorylates the receptor-Smads (R-Smads which are Smads 2 
and 3) that associate with the Co-Smads (Smad4). This entire Smad complex then 
translocates to the nucleus where it interacts with promoter regions of different 















Epigenetic Silencing of TGFβRII 
Mutation of TGFβRII is common microsatellite instability CRC. However, 
TGFβRII is commonly lost in microsatellite stable CRC. This is achieved through 
epigenetic silencing. Many studies have shown that neither promoter mutation 
nor DNA methylation is responsible for the silencing of TGFβRII. Chromatin 
immunoprecipitation (ChIP) revealed that at the TGFβRII promoter there was a 
decreased histone 3 (H3) acetylation and an increased histone3lysine9 
trimethylation (H3K9) – suggesting that epigenetic changes (silencing) of the 
TGFβRII promoter are responsible for its loss in cancer. These epigenetic changes 
are mediated by histone deactylases (HDACs) or histone methytransferases 
(HMTs) [212, 213]. 
Histone Deacetylases 
The acetylation status of the H-amino of lysines on histones renders chromatin 
active or inactive. The addition of the negative charge opens up the chromatin 
structure for active transcription Hyperacetylation is associated with active 
transcription while hypoacetylation is responsible for gene repression [130, 131]. 
(HDACs are classified into 4 main classes – Classes I, II, III and IV. Of these, the 
class III HDACs are called sirtuins and require Nad+ for their activity while the 
other three classes require a Zn2+ cation for their function. There are a total of 11 
HDACs plus sirtuins that fall in the HDAC category [132, 133].  
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HDACs are overexpressed in many kinds of cancers including CRC and are 
usually associated with poor prognosis [214-221]. (Figure 3) Osada and co-
workers studied the epigenetic silencing of TGFβRII in lung cancer cell lines and 
showed increased H3K9 methylation (silencing) and decreased H3K4 (activation) 


























Histone methytransferases (HMTs) 
Histone methylation usually occurs on H-lysines of histones 3 and 4 and can be 
associated with both gene activation and silencing [130, 224]. G9a is an HMT that 
catalyzes the histone-3 lysine-9 methylation (H3K9me) and this reaction is 
usually associated with euchromatic gene silencing. G9a and G9a-like protein 
partner with each other and are responsible for the H3K9methylation, which can 
be either mono- or di-methylation [225, 226].  
EZH2 is yet another HMT that is part of the polycomb repressive complex and is 
responsible for H3K27 methylation that is again associated with gene silencing 
[227]. The roles of HMTs in the silencing of TGFβRII have not been studied yet 
but since there is plasticity in epigenetic silencing, it is likely that methylation 
works in concert with deacetylation to produce the observed transcriptional 
repression [227, 228].  
HDAC inhibitors (HDACi’s) 
HDACs are aberrantly overexpressed in different cancer and therefore present 
themselves as excellent therapeutic targets. Development of the different 
HDACi’s was based on their chemical structure and their ability to obstruct the 
Zn2+ cation that is required for HDAC activity [229, 230]. The pan-HDACi’s are 
selective for Class I, II and IV HDACs but do not affect sirtuins [231]. Initial pan-
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HDACi’s inhibited all HDACs to differing degrees but more class selective 
HDACi’s are now becoming available [232, 233]. 
The different chemical groups are as follows:  
1. Hydroxamic acids (TSA and Vorinostat) 
2. Carboxylic acid (Valproate and Butyrate) 
3. Aminobenzamides (Etinostat and Mocetinostat) 
4. Cyclic peptides (Apicidin, Romidepsin) 
5. Epoxyketones (Trapoxin) 
x MGCD0103 (Mocetinostat) 
This is an aminobenzamide HDAC inhibitor that inhibits HDACs 1, 2, 3 
and 11 at nanomolecular ranges and is most effective against HDACs1 
and 2. It has the ability to prevent cell proliferation, cause cell cycle arrest 
with the induction of p21 and is active in-vitro for about 48hrs. The drug 
is knows to affect only cancer cells and not normal human cells, so 
providing a therapeutic index [234-238].  
x Droxinostat 
This HDACi is a hydroxamic acid moiety that inhibits HDACs 3, 6 and 8 
and is able to cause cancer cell death by activating the death ligands FAS 
and tumor necrosis factor related apoptosis inducing ligand. The 
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hydroxamic acid moiety is important for its function. It inhibits HDAC 6 
and 8 at much lower concentrations than it does HDAC3 [239, 240].  
HMT inhibitors: 
These inhibitors have the ability to prevent the methylation of histones and so 
permit the transcription of TSGs.  Drugs developed against HMTs include 
UNC0638 (G9a inhibitor), EPZ004777 (DOTL1 inhibitor), AZO5 (SMYD2 
inhibitor) and DZNEP (EZH2 inhibitors) [241].  
x UNC0638 (UNC) 
 It is a selective inhibitor of G9a and GLP in the low nanomolar range. It 
functions by blocking the enzymatic activity of G9a/GLP and therefore 
does not affect protein or mRNA levels. It inhibits H3K9 methylation with 
high potency and low toxicity [242, 243].  
x DZNEP 
This selective inhibitor of EZH2 exhibits only mild toxicity against normal 
human cells. The drug has proven to be anti-tumorigenic in breast, lung, 
brain, prostate and liver cancer. It has the ability to inhibit cell migration 
and invasion. DZNEP when combined with HDACi Panobinostat had 




Rationale and Hypothesis: 
The Brattain Laboratory has shown that introduction of TGFβRII through 
genetic expression into CRC with epigenetically silenced receptor decreases 
tumorigenecity and metastatic capacity. Conversely, introduction of a dominant 
negative TGFβRII into the FET CRC cell line, which retains low levels of TGFβ 
signaling, results in acquisition of tumorigenecity in vivo. Therefore, reactivation 
of expression of TGFβRII in CRC, where this tumor suppressor gene (TSG) is 
epigenetically silenced might represent a potential useful therapeutic strategy 
given the growth inhibitory and anti-metastatic effects of the TGFβ signaling 
pathway. The development of epigenetic drugs affords an opportunity to utilize 
this potential therapeutic benefit. However, current HDACi’s inhibit all classes of 
HDACs except the sirtuins. Identification of the epigenetic enzymes (HDACs 
and HMTs) involved in the epigenetic silencing of TGFβRII would allow for the 
development of improved therapy, due to fewer off target effects.  
Previous work in our lab demonstrated that pan-HDACi Belinostat was able to 
induce the expression of the TSG TGFβRII in CRC cell lines with epigenetically 
silenced TGFβRII. Induction of TGFβRII was associated with decrease in 
inhibitor of apoptosis (IAP) proteins X-linked IAP (XIAP) and survivin [211].  
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Belinostat is a pan-HDAC and inhibits all classes of HDACs except Class III 
HDACs (sirtuins) and therefore is associated with higher incidence of side and 
off-target effects[249]. Therapy would be improved by the development of more 
selective HDACs. Therefore there is a need to discover the HDACs responsible in 
the silencing of TGFβRII and develop therapeutic HDACi’s to target them. The 
TGFβRII promoter lacks a specific transcription start site (no TATA box) but 
contains GC boxes, which bind Sp1 and Sp3. The Brattain laboratory reported 
that on HDACi treatment, Sp3 becomes acetylated by p300. Sp1 and Sp3 are 
bound to HDACs that cause TGFβRII to stay in an inactive state. On treatment 
with HDACi TSA, acetylated Sp3 along with Sp1 acts as a transcriptional 
activator leading to the reactivation of expression of TGFβRII [250]. (Figure 4) 
The induction of TGFβRII upon treatment with pan-HDACi’s points to an 
essential role of HDACs in the silencing of TGFβRII. Futher, although histone 
methylation status changes with TGFβRII induction, the HMTs involved in 
TGFβRII silencing have not been studied [223].                    
Therefore we hypothesize that the identification of the specific HDAC/HDACs or 
HMT/HMTs involved in the reactivation of epigenetically silenced TGFβRII 
would allow the use of more specific HDACi’s/HMT inhibitors which would 
increase the therapeutic index of these drugs, decrease side effects and permit 














Materials and Methods: 
Cell culture and Reagents 
CRC cell lines were derived from patient tumors and grown in serum free (SF) 
medium that contains Supplemental McCoy’s 5A (Sigma Aldrich), 5ng/ml 
epidermal growth factor (EGF) (R&D Systems), 20µg/ml insulin (Sigma) and 
4µg/ml transferrin (Sigma). 
The FET cell line is non-tumorigenic and retains low levels of TGFE signaling. 
The CBS cell line retains metastatic capability [163, 164].  
All cell lines were grown and incubated at 37qC in a humidified atmosphere of 
6% CO2.  
MGCD0103 (S1122) and Droxinostant (S1422) were purchased from Selleck, 
while UNC0638 (U4885) and DZNEP (SML0305) were purchased from Sigma-
Aldrich.  
Western Blotting and Antibodies:  
Colon cancer as well pancreatic cancer cells were grown to the required number 
days for confluence after drug treatment. Cells were washed 3 times with cold 
phosphate buffer saline (PBS) that contains 0.1% EDTA. Washed cells were 
scraped and lysed with TNESV buffer [50mmol/L Tris (Ph 7.5), 150mmol/L NaCl, 
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1% NP40, 50mmol/L NaF, 1mmol/L Na3VO4, 25μg/ml β-glycerophosphate, 
1mmol/L phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor cocktail 
(Roche,Indianapolis, IN)]. After 30min incubation with the lysis buffer, cells were 
centrifuged at 14000g’s for 20min at 4qC. The supernatant was extracted and 
protein in it was quantified using the bicinchoninic acid(BCA; Pierce). The 
protein was diluted in SDS sample buffer (50mM Tris, ph 6.8, 1% SDS, 10% 
glycerol, 0.03% bromophenol blue and 1% β-mercaptoethanol) and separated by 
SDS-PAGE (7.5-15% gels). The gels were then transferred by electroblotting 
(100V for 90min or overnight at 10V) onto a nitrocellulose membrane (GE 
Amersham). Post transfer, the membrane was blocked with 5% non-fat dry milk 
in TBS-T (150mmol/L NaCl, 10mmol/L Tris-HCl pH7.4, 0.05% Tween 20) for 1hr 
at room temperature or overnight at 4°C.  The membrane was cut at requisite 
molecular weights and primary antibody was added in either 5% non-fat dry 
milk or 5% bovine serum albumin (BSA) in TBS-T for 2hr at room temperature or 
overnight at 4°C according to the antibody data sheets.  The membrane was 
washed three times for 10min in TBS-T and the appropriate secondary was 
added in 5% non-fat dry milk for 1hr at room temperature. The membrane was 
washed three more times with TBS-T for 10min at room temperature and the 
proteins were detected by the enhanced chemiluminescence system (ECL; GE 
Amersham). TGFERII (sc-177799) antibody was purchased from Santa Cruz.  
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pSmad3 (#9520) HDAC1(#2062), HDAC2(#5113), HDAC3(#3949), Survivin 
(#2308), G9a (#3306) and EZH2(#5246) antibodies were purchased from Cell 
Signaling. GAPDH (G8795) was acquired from Sigma.   
Transient transfection:  
HDAC2 (sc-29345) and HDAC3 (sc-35538) siRNA were purchased from Santa 
Cruz Biotechnology Inc., and knockdown was performed according to the 
manufacturer's protocol.   
Stable transfection:  
HDAC1 shRNA  (sc-29343) was purchased from Santa Cruz Biotechnology Inc. 
FET and CBS cell lines were plated in 10cm plates in serum free medium which 
was changed to Opti-MEM media (Invitrogen), when they were 40% confluent. 
The cells were transfected with a pool of 3 shRNA’s directed against HDAC1. 









1. MGCD0103 induces TGFERII (RII) in colon cancer cells and reduces cell 
survival. 
In order to begin to dissect the specific HDACs involved in the epigenetic 
silencing of TGFERII, we used some of the newer generation HDACi’s 
which exhibit a more limited range of HDAC selectivity. Mocetinostat 
(MGCD0103) inhibits HDACs 1, 2, 3 and 11. We first tested the effect of 
this drug on the CBS cell line that has an epigenetically silenced TGFERII, 
and FET cells which retain a low level of TGFE signaling. MGCD0103 
induced increased TGFERII expression by 48hrs. (Figure 1a) The induction 
was dose dependent. This induction of TGFERII was accompanied by a 
dose-dependent decrease in IAP protein, survivin.  
We next determined whether MGCD0103 would induce TGFERII 
expression in the CBS CRC cell line that has an epigenetically silenced 
TGFERII and lacks functional TGFE signaling. Again MGCD0103 induced 








Figure 1a: Mocetinostat (MGCD) inhibits HDACs 1, 2, 3 and 11 and 
induces expression of TGFERII at 48hours in a dose dependent manner, 
accompanied by a decrease in IAP protein, survivin; in the FET CRC cell 












Figure 1b: Mocetinostat (MGCD) inhibits HDACs 1, 2, 3 and 11 and 
induces expression of TGFERII at 48hours in a dose dependent manner, 
accompanied by a decrease in IAP protein, survivin; in the CBS CRC 
cell line which has epigenetically silenced TGFERII. CBS cells were 
treated with Belinostat, a pan-HDACi at 500nm for 48hrs as a positive 








2. Inhibition of HDACs 3, 6 and 8 by Droxinostat does not induce 
TGFERII in CRC cell lines. 
Droxinostat inhibits the ClassII HDACs 6 and 8 with IC50 of 2.47 and 1.46 
µm, respectively, with inhibition of HDAC3 at around 10-fold higher 
concentrations. Treatment of the CBS CRC cell line, which has 
epigenetically silenced TGFERII, with Droxinostat did not induce TGFERII 
at 10um. TGFERII expression was restored to control level at 25µm which 











Figure 2. Treatment of the CBS CRC cell line with Droxinostat saw no 
induction of TGFERII at the lower concentrations but levels equivalent 
to the control at higher concentrations, when HDAC3 would get 










3. Genetic approaches to confirm that HDAC1 and HDAC3 are involved in 
the epigenetic silencing of TGFERII.  
The drug studies indicate that HDAC1 and HDAC3 may be key players in 
the epigenetic silencing of TGFERII. Therefore, we performed stable 
knockdown (KD) of HDAC1, generating clones 7 and 9 in the FET CRC 
cell line and clones 6 and 17 in the CBS CRC cell line. siRNA was used to 
knock down HDACs 2 and 3 and TGFERII expression was determined.  
KD of HDAC2 was performed as a control to confirm that only the KD of 














                                                                                                                                
Figure 3a: KD of HDAC1 in both the FET and CBS CRC cell lines 





                                                                                                                                   
Figure 3b: KD of HDAC2 in both the FET and CBS CRC cell lines did 
not induce TGFERII expression. Data shown are representative of three 







                                                                                                                                    
Figure 3c: KD of HDAC3 in both the FET and CBS CRC cell lines caused 
the re-expression of TGFERII. Data shown are representative of three 










4. The role of HMTs G9a and EZH2 in the epigenetic silencing of 
TGFERII. 
The role of HDACs in the epigenetic silencing of TGFERII has been well 
established. However, epigenetic silencing also involves histone 
methylation. We hypothesized that HMTs activity might be involved in 
the epigenetic silencing of TGFERII. Therefore in order to address whether 
HMTs are involved in the silencing of TGFERII we used specific G9a and 
EZH2 inhibitors, UNC0638 and DzNEP, respectively.  
 Treatment of CRC cell lines CBS with UNC0638 allowed for the re-
expression of TGFERII in a time dependent manner- with maximal effect 
at 48 hours and in a dose dependent manner. Whole cell lysates from FET 
cells treated with Belinostat were run as positive control.  
To confirm that the inhibition of G9a was inducing the expression of 
TGFERII and reactivating the TGFE inhibitory pathway, we examined the 
phosphorylation status of Smad3 upon activation. Smad3 is 
phosphorylated when the canonical TGFE pathway is activated. Smad3 







Figure 4: Treatment of CBS cell line that has epigenetically silenced TGFERII, 
with UNC0638 (UNC), induced TGFERII in a time and dose-dependent 
manner. pSmad3 induction confirmed the activation of the canonical TGFE 




5. Inhibition of HMT DzNEP induces expression of TGFERII in a time 
and dose-dependent manner.  
Treatment of CRC cell line CBS with DzNEP allowed for the re-expression 
of TGFERII in a time-dependent manner with a maximal effect at 48 hours 
and in a dose-dependent manner at both 24 and 48 hours. Whole cell FET 
lysates treated with Belinostat were used a positive control.  
To confirm the re-expression of TGFERII, through the inhibition of EZH2, 
was reactivating the TGFE inhibitory pathway, we investigated the effect 
of DzNEP on Smad3 phosphorylation.by adding TGFE to the DzNEP 
treated cells, 1 hour before harvest and as observed in CBS cells,  DzNEP 














Figure 5: Treatment of CBS cell line that has epigenetically silenced TGFERII, 
with DzNEP, induced TGFERII in a time and dose-dependent manner. 
pSmad3 induction confirmed the activation of the canonical TGFE signaling 




6. Interaction between HDACs and HMTs in the epigenetic silencing of 
TGFERII. 
Our data indicate that HMTs are involved in the epigenetic silencing of 
TGFERII as inhibition of those enzymes results in the induction of 
TGFERII expression. However, HDAC inhibition alone is sufficient to 
induce TGFERII expression without additional HMT inhibition. Therefore, 
we hypothesized that HDAC inhibition might decrease HMT activity 
allowing for HDAC inhibition alone to induce expression of TGFERII.  
Conversely, we examined the effect of the HDACi Belinostat on the 
expression of G9a and EZH2. Belinostat treatment of FET CRC cells 
resulted in a dose-dependent decrease in G9a and EZH2 24 hours. 
Previous work done in the Brattain laboratory has confirmed that pan-









Figure 7: Treatment of FET CRC cell line with Belinostat decreases HMTs, G9a 
and EZH2 confirming the dual role of HDACi’s of inhibiting HDACs as well 
as regulating HMT status at gene promoters. Data shown are representative of 





The mutational changes underlying the development and progression of CRC 
have been well documented [192]. Mutations in TSG’s or oncogenes result in TSG 
silencing or oncogene activation. These mutational changes are common in the 
microsatellite instability phentoype of CRC [251, 252]. However, recently the 
importance of epigenetic changes, which lead to TSG silencing or oncogene 
activation, have been recognized [253-255]. Epigenetic regulation involves 
modification of DNA histones or other DNA binding proteins that affects 
chromatin conformation that either activates or represses transcription of genes 
at the altered site.  
DNA methylation and histone modifications are two such epigenetic events that 
occur in the cell. Histone modifications include acetylation and/or methylation of 
the lysine tails of the histones around which DNA wraps. Histone acetylation is 
brought about by HATs and is usually associated with gene activation where 
histone deacetylation is brought on by HDACs and is associated with gene 
repression.  These changes, unlike DNA sequence mutation, are potentially 
reversible if the specific enzymes facilitating the modifications are targeted. 
Therefore, epigenetic therapy has the potential to target cancer through silencing 
of oncogenes or activation of silenced TSG’s [256]. 
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The Brattain laboratory has extensively documented the anti-tumorigenic 
abilities of the TSG TGFERII. Previous work confirmed that the HDACi 
Belinostat induces expression of TGFERII [211]. However two aspects of the 
silencing of TGFERII were not understood: – (i) the role of specific HDACs 
involved in the silencing, and (ii) the potential role of HMTs in the silencing of 
TGFERII. 
We hypothesized that identification of the specific HDACs and/or HMTs 
involved in the silencing of TGFERII will allow us to develop drugs specific to 
those HDACs and/or HMTs, so reducing off-target effects resulting in reduced 
toxicities. We employed both pharmacological and genetic approaches to 
indentify the specific epigenetic regulators involved in the epigenetic silencing of 
TGFERII.  
We treated CRC cell lines with MGCD0103, which selectively inhibits HDACs 1, 
2, 3 and 11 at nanomolar values [235]. Inhibition of these HDACs resulted in an 
induction of TGFERII in FET cells at 48 hrs and in CBS cells at 24 hrs as well as 48 
hrs. FET is a non-metastatic cell line that expresses low-level autocrine TGFE 
signaling. In contrast CBS is a metastatic cell line with silenced TGFERII 
expression and so lacks inhibitory TGFE signaling. MGCD0103 caused a robust 
re-expression of TGFERII confirming that HDAC1, 2, 3 and/or 11 are probably 
involved in its silencing. In contrast, treatment with Droxinostat, which inhibits 
146 
 
HDAC 6 and 8 (IC50 2.47µm and 1.46µm, respectively) and HDAC3 at high 
micromolar concentration (IC50 = 20µm) did not induce TGFERII [239, 240]. 
There appeared to be slight induction of the TGFERII expression at the 25µm 
dose at which HDAC3 would be inhibited. These pharmacological studies 
pointed to the involvement of of HDACs 1 and 3 in the epigenetic silencing of 
TGFERII.  
In order to confirm the roles of HDACs 1 and 3 , we developed stable HDAC1 
knockdown clones in both FET and CBS cell lines. We successfully developed the 
HDAC2 KD as a control. The KD of HDAC1 resulted in re-expression of 
TGFERII. The same result was observed upon KD of HDAC3 but HDAC2 had no 
effect on TGFERII expression. This confirmed that HDACs 1 and 3 are the major 
HDACs involved in the epigenetic silencing of TGFERII. Based on the work 
done, we were able to confirm the roles of HDACs 1 and 3 in the silencing of the 
TSG TGFERII.  
Histone methylation is also involved in epigenetic silencing. G9a is a H3K9 
methyltransferase while EZH2 is a H3K9 as well as H3K27 methyltransferase. 
These methytransferases are capable of di- and tri-methylation and can be 
associated with gene activation or repression. There is no literature published 
confirming a relationship between G9a and the epigenetic silencing of TGFERII. 
While the relationship between the cytokine TGFE and EZH2 has been studied, 
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the potential role of EZH2 in the epigenetic silencing of TGFERII has not been 
investigated. We therefore examined the role of G9a and EZH2 in the silencing of 
TGFERII.  
UNC0638 inhibits both G9a and its partner GLP at low nanomolecular levels 
[242]. On treating the CRC cell lines with this drug we observed an induction of 
TGFERII in a time and dose-dependent manner. Reactivation of the TGFE 
inhibitory pathway was confirmed by the phosphorylation of Smad3. We were 
able to obtain similar results by the inhibition of EZH2 by DZNEP [245].  These 
preliminary studies confirmed that G9a as well as EZH2 play a role in the 
silencing of TGFERII and contribute to tumorigenesis as well progression of 
CRC.  
These findings also raised an inherent question. HDACi’s such as Belinostat and 
MGCD0103 are sufficient to induce re-expression of TGFERII but clearly histone 
methylation is involved in the silencing too. We therefore hypothesize that 
HDACi’s might regulate the HMTs, G9a and EZH2. Panobinostat, a pan-HDACi 
decreased EZH2 levels in acute leukemia cells and enhanced cancer cell survival 
[257]. Belinostat treatment of the FET CRC cells decreased G9a and EZH2. 
Therefore, though HDACi’s predominantly regulate histone deacetylation at 
gene promoters, they can also play a role in histone methylation status through 




x Chromatin Immunoprecipitation studies of the TGFERII promoter will 
give insight of the on the actual interaction between the HDACs 1 and 3 
and the promoter region. 
Confirm that the knockdown of HDACs 1 and 3 allows for active 
inhibitory TGFE signaling by examining the phosphorylation status of 
Smad3. Confirm that re-expression of TGFERII decreases survivin and 
XIAP through western blot analysis.  
x Knockdown of G9a and EZH2 using siRNA and confirmation of their 
association with the TGFERII promoter using chromatin 
immunoprecipitation.  
Confirm that knockdown of G9a and EZH2 activates the inhibitory TGFE 
signaling pathway by examining the phosphorylation status of Smad3. 
Confirm that re-expression of TGFERII decreases survivin and XIAP 
through western blot analysis .  
Conclusions:  
My study has confirmed the role of HDACs 1 and 3 in the silencing of TSG 
TGFERII in CRC. We also confirmed that HDACi’s have the ability not only to 
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